Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Identifying metabolic dependencies of breast stem and progenitor cells

FY 2016-17

Summary
Progesterone exposure and BRCA1/2 status are two major risk factors that predispose women to breast cancer. Treatment options are limited for young women at higher lifetime risk of breast cancer, as it often involves invasive mastectomies or surveillance programs. Mammary stem and progenitor cells are putative targets of transformation in breast cancer, yet strategies to eliminate these precursor cells are currently lacking. The Khokha Lab has made considerable efforts establishing a program designed to develop precise chemopreventative strategies for women at high-risk of breast cancer. We recently completed global proteomics to understand the protein composition of primary cells that make up the mammary epithelial hierarchy. These cells serve as putative cell(s)-of origin in breast cancer, thus building new capacity to identify dependencies of these primitive cell types.Metabolism was identified as as key process underlying adult stem and progenitor expansion.We therefore hypothesize that these metabolic dependencies could be targeted and exploited in order to deplete the mammary stem and progenitor populations. Metabolic targets will be matched to clinically used drugs that we hope to repurpose as chemopreventative agents for high-risk breast cancer patients. Patient samples will be used to establish drug responsiveness of human progenitors from different groups of high-risk women. Top drugs will also be tested in mouse models of precancerous breast cancer and also patient-derived, human tumour formation in mice. The ability of these drugs to abrogate stem and progenitor activity and tumour formation has wide reaching implications not just for preventative regimens, but also for targeting breast cancer stem cells.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367237
Name
Mahendralingam Mathepan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying metabolic dependencies of breast stem and progenitor cells
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brca1/2; Breast Cancer; Cell Of Origin; Chemoprevention; Mammary Gland; Metabolism; Progesterone; Proteome; Stem Cell
Abstract
Progesterone exposure and BRCA1/2 status are two major risk factors that predispose women to breast cancer. Treatment options are limited for young women at higher lifetime risk of breast cancer, as it often involves invasive mastectomies or surveillance programs. Mammary stem and progenitor cells are putative targets of transformation in breast cancer, yet strategies to eliminate these precursor cells are currently lacking. The Khokha Lab has made considerable efforts establishing a program designed to develop precise chemopreventative strategies for women at high-risk of breast cancer. We recently completed global proteomics to understand the protein composition of primary cells that make up the mammary epithelial hierarchy. These cells serve as putative cell(s)-of origin in breast cancer, thus building new capacity to identify dependencies of these primitive cell types.Metabolism was identified as as key process underlying adult stem and progenitor expansion.We therefore hypothesize that these metabolic dependencies could be targeted and exploited in order to deplete the mammary stem and progenitor populations. Metabolic targets will be matched to clinically used drugs that we hope to repurpose as chemopreventative agents for high-risk breast cancer patients. Patient samples will be used to establish drug responsiveness of human progenitors from different groups of high-risk women. Top drugs will also be tested in mouse models of precancerous breast cancer and also patient-derived, human tumour formation in mice. The ability of these drugs to abrogate stem and progenitor activity and tumour formation has wide reaching implications not just for preventative regimens, but also for targeting breast cancer stem cells.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mahendralingam, Mathepan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~